Goldman Sachs Group Inc Magenta Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 May 14, 2024	SELL	$0.36 - $1.59 $26,532 - $117,186	-73,702 Reduced 65.95%	38,059 $15,000
Q4 2022 Feb 13, 2023	SELL	$0.36 - $1.59 $26,532 - $117,186	-73,702 Reduced 65.95%	38,059 $15,000
Q3 2022 May 14, 2024	SELL	$1.26 - $2.09 $13,388 - $22,208	-10,626 Reduced 8.68%	111,761 $158,000
Q3 2022 Nov 10, 2022	SELL	$1.26 - $2.09 $13,388 - $22,208	-10,626 Reduced 8.68%	111,761 $0
Q2 2022 May 14, 2024	BUY	$0.97 - $3.08 $118,715 - $376,951	122,387 New	122,387 $147,000
Q2 2022 Aug 15, 2022	SELL	$0.97 - $3.08 $38,501 - $122,251	-39,692 Reduced 24.49%	122,387 $147,000
Q1 2022 May 16, 2022	SELL	$2.55 - $5.23 $63,599 - $130,441	-24,941 Reduced 13.34%	162,079 $470,000
Q4 2021 Feb 14, 2022	BUY	$4.43 - $8.33 $67,110 - $126,191	15,149 Added 8.81%	187,020 $829,000
Q3 2021 Nov 10, 2021	BUY	$6.07 - $9.89 $1.04 Million - $1.7 Million	171,871 New	171,871 $1.25 Million

442K

Ticker MGTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,890,500
Description
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that ca...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.